Bioresponsive Self-Reinforcing Sericin/Silk Fibroin Hydrogel for Relieving the Immune-Related Adverse Events in Tumor Immunotherapy |
| |
Authors: | Shuangquan Gou Weilin Meng Adriana C Panayi Rong Wang Rui Zhang Pengfei Gao Tingting He Wenbo Geng Shi Hu Yongsheng Yu Qian Feng Kaiyong Cai |
| |
Affiliation: | 1. Key Laboratory of Biorheological Science and Technology, Ministry of Education, Collage of Bioengineering, Chongqing University, Chongqing, 400044 China;2. Department of Hand, Plastic and Reconstructive Surgery, Microsurgery, Burn Center, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwig-Guttmann-Strasse 13, 67071 Ludwigshafen/Rhine, Germany;3. Department of Biophysics, Naval Medical University, Shanghai, 200433 China;4. Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, 400714 China |
| |
Abstract: | Despite the immense potential of immune checkpoint blockade (ICB) therapy in tumor treatment, its widespread clinical application is currently limited by unsatisfactory curative effect and off-target adverse effect. Herein, an injectable sericin (SS)/silk fibroin (SF) recombinant hydrogel, termed SF-SS-SMC hydrogel, is developed to enable local delivery of anti-CD47 antibody (α CD47). The hydrogel displays self-reinforcement in high H2O2 concentration of tumor microenvironment (TME), as the SS/Fe2+ supramolecular nanocomplex (SS-SMC) inside the hydrogel converts H2O2 to reactive oxygen species (ROS), further triggering additional crosslinking among the SF polymers. Therefore, the SF-SS-SMC hydrogel has an in vivo retention time longer than 21 days and acts as a reservoir for the long-term sustained release of α CD47. More importantly, the SF-SS-SMC hydrogel itself efficiently regulates the remodeling of a protumor immunosuppressive TME to an antitumoral TME through switching of tumor-associated macrophages from an anti-inflammatory M2 phenotype to a proinflammatory M1 phenotype without additional drugs. Based on the combined effect of sustained α CD47 release and TME reprogramming, the SF-SS-SMC hydrogel has satisfactory immunotherapeutic effects in the treatment of local, abscopal, remitting, and metastatic tumors. Further advantages, including low cost of production, simple fabrication, and ease of use, make it promising for commercial mass production. |
| |
Keywords: | injectable hydrogels responsive self-reinforcement silk-based biomaterials TAM reeducation tumor immunotherapy |
|
|